CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations

Epilepsy Research

Volumn 106, Issue 1-2, 2013, Pages 74-82

  Citraro, Rita ^a   Russo, Emilio ^a   Ngomba, Richard T ^b   Nicoletti, Ferdinando ^b,c   Scicchitano, Francesca ^a   Whalley, Benjamin J ^d   Calignano, Antonio ^e   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b IRCCS NEUROMED   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF READING   (United Kingdom)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anandamide; CB receptors; Rimonabant; Seizure; WAG Rij rats; WIN55,212

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR AGONIST; RIMONABANT;

ABSENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENETIC ABSENCE EPILEPSY; GENETIC DISORDER; GENETIC MODEL; MALE; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; RAT; SOMATOSENSORY CORTEX; THALAMUS NUCLEUS; VENTROPOSTEROMEDIAL THALAMIC NUCLEUS;

ANANDAMIDE; CB RECEPTORS; RIMONABANT; SEIZURE; WAG/RIJ RATS; WIN55,212;

ANIMALS; ANTICONVULSANTS; ARACHIDONIC ACIDS; BENZOXAZINES; CANNABINOID RECEPTOR AGONISTS; CEREBRAL CORTEX; ELECTROENCEPHALOGRAPHY; ENDOCANNABINOIDS; EPILEPSY; EPILEPSY, ABSENCE; INJECTIONS, INTRAVENTRICULAR; MALE; MORPHOLINES; NAPHTHALENES; NEURAL PATHWAYS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; SEIZURES; SOMATOSENSORY CORTEX; THALAMUS;

EID: 84883284124     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.06.004     Document Type: Article

References (58)

1. Aguado T., Romero E., Monory K., Palazuelos J., Sendtner M., Marsicano G., Lutz B., Guzman M., Galve-Roperh I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem. 2007, 282:23892-23898.
2. Alger B.E., Kim J. Supply and demand for endocannabinoids. Trends Neurosci. 2011, 34:304-315.
3. Andres-Mach M., Zolkowska D., Barcicka-Klosowska B., Haratym-Maj A., Florek-Luszczki M., Luszczki J.J. Effect of ACEA-a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:301-309.
4. Arya R., Greiner H.M., Lewis A., Mangano F.T., Gonsalves C., Holland K.D., Glauser T.A. Vagus nerve stimulation for medically refractory absence epilepsy. Seizure 2013, 22:267-270.
5. Avanzini G., Manganotti P., Meletti S., Moshe S.L., Panzica F., Wolf P., Capovilla G. The system epilepsies: a pathophysiological hypothesis. Epilepsia 2012, 53:771-778.
6. Blair R.E., Deshpande L.S., Sombati S., Falenski K.W., Martin B.R., DeLorenzo R.J. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J. Pharmacol. Exp. Ther. 2006, 317:1072-1078.
7. Blumenfeld H., McCormick D.A. Corticothalamic inputs control the pattern of activity generated in thalamocortical networks. J. Neurosci. 2000, 20:5153-5162.
8. Bojnik E., Turunc E., Armagan G., Kanit L., Benyhe S., Yalcin A., Borsodi A. Changes in the cannabinoid (CB1) receptor expression level and G-protein activation in kainic acid induced seizures. Epilepsy Res. 2012, 99:64-68.
9. Bouma P.A., Westendorp R.G., van Dijk J.G., Peters A.C., Brouwer O.F. The outcome of absence epilepsy: a meta-analysis. Neurology 1996, 47:802-808.
10. Cakil D., Yildirim M., Ayyildiz M., Agar E. The effect of co-administration of the NMDA blocker with agonist and antagonist of CB1-receptor on penicillin-induced epileptiform activity in rats. Epilepsy Res. 2011, 93:128-137.
11. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 2001, 20:7033-7040.
12. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 2006, 29:37-76.
13. Citraro R., Russo E., Di Paola E.D., Ibbadu G.F., Gratteri S., Marra R., De Sarro G. Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006, 50:1059-1071.
14. Citraro R., Russo E., Gratteri S., Di Paola E.D., Ibbadu G.F., Curinga C., Gitto R., Chimirri A., Donato G., De Sarro G. Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology 2006, 51:1058-1067.
15. Citraro R., Russo E., Scicchitano F., van Rijn C.M., Cosco D., Avagliano C., Russo R., D'Agostino G., Petrosino S., Guida F., Gatta L., van Luijtelaar G., Maione S., Di Marzo V., Calignano A., De Sarro G. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-alpha receptor activation in a genetic model of absence epilepsy. Neuropharmacology 2012, 69:115-126.
16. Citraro R., Scicchitano F., De Fazio S., Raggio R., Mainardi P., Perucca E., De Sarro G., Russo E. Preclinical activity profile of alpha-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Res. 2011, 95:60-69.
17. Crunelli V., Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat. Rev. Neurosci. 2002, 3:371-382.
18. D'Alimonte I., D'Auro M., Citraro R., Biagioni F., Jiang S., Nargi E., Buccella S., Di Iorio P., Giuliani P., Ballerini P., Caciagli F., Russo E., De Sarro G., Ciccarelli R. Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. Eur. J. Neurosci. 2009, 30:1023-1035.
19. Deshpande L.S., Blair R.E., Ziobro J.M., Sombati S., Martin B.R., DeLorenzo R.J. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur. J. Pharmacol. 2007, 558:52-59.
20. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 2009, 60:77-84.
21. Diana M.A., Marty A. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br. J. Pharmacol. 2004, 142:9-19.
22. Drysdale A.J., Platt B. Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr. Med. Chem. 2003, 10:2719-2732.
23. Han J., Kesner P., Metna-Laurent M., Duan T., Xu L., Georges F., Koehl M., Abrous D.N., Mendizabal-Zubiaga J., Grandes P., Liu Q., Bai G., Wang W., Xiong L., Ren W., Marsicano G., Zhang X. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012, 148:1039-1050.
24. Hill A.J., Weston S.E., Jones N.A., Smith I., Bevan S.A., Williamson E.M., Stephens G.J., Williams C.M., Whalley B.J. Delta(9)-tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 2010, 51:1522-1532.
25. Hill A.J., Williams C.M., Whalley B.J., Stephens G.J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther. 2012, 133:79-97.
26. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
27. Karlocai M.R., Toth K., Watanabe M., Ledent C., Juhasz G., Freund T.F., Magloczky Z. Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy. PLoS ONE 2011, 6:e27196.
28. Luttjohann A., van Luijtelaar G. Thalamic stimulation in absence epilepsy. Epilepsy Res 2013, S0920-1211(13)00094-6. 10.1016/j.eplepsyres.2013.03.009.
29. Manna S.S., Umathe S.N. Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures. Epilepsy Res 2012, 100:113-124.
30. Manning J.P., Richards D.A., Leresche N., Crunelli V., Bowery N.G. Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience 2004, 123:5-9.
31. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
32. Meeren H.K., Pijn J.P., Van Luijtelaar E.L., Coenen A.M., Lopes da Silva F.H. Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J. Neurosci. 2002, 22:1480-1495.
33. Meier M.H., Caspi A., Ambler A., Harrington H., Houts R., Keefe R.S., McDonald K., Ward A., Poulton R., Moffitt T.E. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl. Acad. Sci. USA 2012, 109:E2657-E2664.
34. Naderi N., Ahmad-Molaei L., Aziz Ahari F., Motamedi F. Modulation of anticonvulsant effects of cannabinoid compounds by GABA-A receptor agonist in acute pentylenetetrazole model of seizure in rat. Neurochem. Res. 2011, 36:1520-1525.
35. Ohno-Shosaku T., Tanimura A., Hashimotodani Y., Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 2012, 18:119-132.
36. Onat F.Y., van Luijtelaar G., Nehlig A., Snead O.C. The involvement of limbic structures in typical and atypical absence epilepsy. Epilepsy Res. 2013, 103:111-123.
37. Panayiotopoulos C.P. The new ILAE report on terminology and concepts for organization of epileptic seizures: a clinician's critical view and contribution. Epilepsia 2011, 52:2155-2160.
38. Patsalos P.N. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 2005, 46(Suppl. 9):140-148.
39. Richards D.A., Manning J.P., Barnes D., Rombola L., Bowery N.G., Caccia S., Leresche N., Crunelli V. Targeting thalamic nuclei is not sufficient for the full anti-absence action of ethosuximide in a rat model of absence epilepsy. Epilepsy Res. 2003, 54:97-107.
40. Russo E., Citraro R., Davoli A., Gallelli L., Donato Di Paola E., De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013, 64:371-379.
41. Russo E., Citraro R., De Fazio S., Marra R., Gitto R., Chimirri A., De Sarro G., Di Paola E.D. Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy. Epilepsy Behav. 2008, 13:295-299.
42. Russo E., Citraro R., De Fazio S., Torcasio G., De Sarro G., Di Paola E.D. Effects of ethanol on the development of genetically determined epilepsies in rats. Int. J. Dev. Neurosci. 2008, 26:739-744.
43. Russo E., Citraro R., Donato G., Camastra C., Iuliano R., Cuzzocrea S., Constanti A., De Sarro G. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2013, 69:25-36.
44. Russo E., Citraro R., Scicchitano F., De Fazio S., Di Paola E.D., Constanti A., De Sarro G. Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia 2010, 51:1560-1569.
45. Russo E., Citraro R., Scicchitano F., De Fazio S., Perrotta I., Di Paola E.D., Constanti A., De Sarro G. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011, 52:1341-1350.
46. Russo E., Citraro R., Scicchitano F., Urzino A., Marra R., Rispoli V., De Sarro G. Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav. Brain Res. 2011, 225:373-376.
47. Russo E., Constanti A., Ferreri G., Citraro R., De Sarro G. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 2004, 46:865-878.
48. Russo E., Scicchitano F., Citraro R., Aiello R., Camastra C., Mainardi P., Chimirri S., Perucca E., Donato G., De Sarro G. Protective activity of alpha-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis. Neuroscience 2012, 226:282-288.
49. Shen M., Thayer S.A. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 1998, 783:77-84.
50. Sun Y.G., Wu C.S., Lu H.C., Beierlein M. Target-dependent control of synaptic inhibition by endocannabinoids in the thalamus. J. Neurosci. 2011, 31:9222-9230.
51. Urbanski M.J., Kovacs F.E., Szabo B. Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling. Synapse 2009, 63:643-652.
52. van Luijtelaar G., Sitnikova E. Global and focal aspects of absence epilepsy: the contribution of genetic models. Neurosci. Biobehav. Rev. 2006, 30:983-1003.
53. van Luijtelaar G., Sitnikova E., Littjohann A. On the origin and suddenness of absences in genetic absence models. Clin. EEG Neurosci. 2011, 42:83-97.
54. van Rijn C.M., Gaetani S., Santolini I., Badura A., Gabova A., Fu J., Watanabe M., Cuomo V., van Luijtelaar G., Nicoletti F., Ngomba R.T. WAG/Rij rats show a reduced expression of CB(1) receptors in thalamic nuclei and respond to the CB(1) receptor agonist, R(+)WIN55,212-2, with a reduced incidence of spike-wave discharges. Epilepsia 2010, 51:1511-1521.
55. Vilela L.R., Medeiros D.C., Rezende G.H., de Oliveira A.C., Moraes M.F., Moreira F.A. Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats. Epilepsy Res. 2013, 104:195-202.
56. Vinogradova L.V., Shatskova A.B., van Rijn C.M. Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy. Epilepsy Res. 2011, 96:250-256.
57. Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., DeLorenzo R.J. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 2003, 307:129-137.
58. Wallace R. Cannabinoids: defending the epileptic brain. Epilepsy Curr. 2004, 4:93-95.